Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin.
Qian XiaoJoseph MearsAparna NathanKazuyoshi IshigakiYuriy BaglaenkoNoha LimLaura A CooneyKristina M HarrisMark S AndersonDavid A FoxDawn E SmilekJames G KruegerSoumya RaychaudhuriPublished in: Nature communications (2023)
Psoriasis is a chronic, systemic inflammatory condition primarily affecting skin. While the role of the immune compartment (e.g., T cells) is well established, the changes in the skin compartment are more poorly understood. Using longitudinal skin biopsies (n = 375) from the "Psoriasis Treatment with Abatacept and Ustekinumab: A Study of Efficacy"(PAUSE) clinical trial (n = 101), we report 953 expression quantitative trait loci (eQTLs). Of those, 116 eQTLs have effect sizes that were modulated by local skin inflammation (eQTL interactions). By examining these eQTL genes (eGenes), we find that most are expressed in the skin tissue compartment, and a subset overlap with the NRF2 pathway. Indeed, the strongest eQTL interaction signal - rs1491377616-LCE3C - links a psoriasis risk locus with a gene specifically expressed in the epidermis. This eQTL study highlights the potential to use biospecimens from clinical trials to discover in vivo eQTL interactions with therapeutically relevant environmental variables.
Keyphrases
- clinical trial
- soft tissue
- wound healing
- oxidative stress
- genome wide
- poor prognosis
- rheumatoid arthritis
- randomized controlled trial
- study protocol
- cross sectional
- risk assessment
- human health
- phase iii
- long non coding rna
- atopic dermatitis
- transcription factor
- systemic lupus erythematosus
- drug induced
- ankylosing spondylitis
- placebo controlled